Panacea Acquisition Corp. II
| IPO Proceeds, $M | $172.50M |
|---|---|
| IPO Date | Apr 7, 2021 |
| CEO | Oleg Nodelman |
| Left Lead | Cowen |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24+(3) |
| IPO Sector |
Healthcare
Biotechnology in North America or Europe |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Apr 19, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Panacea Acquisition Corp. II:
- Structure and cap table
- 9 directors & officers
- 5 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Oleg Nodelman | 44 | CEO & Chairman |
| Scott Perlen | 46 | CFO |
| Scott Platshon | 30 | COO |
| Caroline Stout | 30 | CIO |
| Sarah Marriott | 44 | Secretary and Director |
| Douglas Giordano | 59 | Director |
| Nina Kjellson | 47 | Director |
| Praveen Tipirneni, M.D. | 53 | Director |
| Douglas E. Williams, Ph.D. | 63 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Cowen | BR | 15,000,000 | units |
| 15,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Mar 9, 2021 | Initial S-1 |
| Apr 7, 2021 |
PR announcing pricing of $150mm IPO
Sign In to view filing content. |
| Apr 8, 2021 | 424B4 IPO Prospectus |
| Apr 14, 2021 |
8-K announcing full over-allotment exercise
Sign In to view filing content. |
| Apr 10, 2023 |
8-K announcing liquidation and redemption of public shares
Sign In to view filing content. |